Phase 2 Readouts — Q4 2026
Phase 2 trials test drug efficacy in 100-300 patients with the target condition. Positive Phase 2 data validates the drug mechanism and sets the stage for pivotal Phase 3 trials.
52 phase 2 readouts in Q4 2026. Updated .
Phase 2 Readout: bge-102
BioAge Labs, Inc. (BIOA)
Phase 2 Readout: dt402
Definium Therapeutics Inc. (DFTX)
Phase 2 Readout: orka-001
Oruka Therapeutics, Inc. (ORKA)
Phase 2 Readout: haduvio
Trevi Therapeutics, Inc. (TRVI)
Phase 2 Readout: ampligen
AIM ImmunoTech Inc. (AIM)
Phase 2 Readout: bp1.15205
Harmony Biosciences Holdings, Inc. (HRMY)
Phase 2 Readout: Obesity
BioAge Labs, Inc. (BIOA)
Phase 2 Readout: img-007
ImageneBio, Inc. (IMA)
Phase 2 Readout: azenosertib
Zentalis Pharmaceuticals, Inc. (ZNTL)
Phase 2 Readout: sevasemten
Edgewise Therapeutics, Inc. (EWTX)
Phase 2 Readout: descartes-08
Cartesian Therapeutics, Inc. (RNAC)
Phase 2 Readout: neo100
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)
Phase 2 Readout: type 2 diabetes
Biomea Fusion, Inc. (BMEA)
Phase 2 Readout: revita
Fractyl Health Inc. (GUTS)
Phase 2 Readout: dabogratinib
Tyra Biosciences, Inc. (TYRA)
Phase 2 Readout: budoprutug
Climb Bio, Inc. (CLYM)
Phase 2 Readout: abs-201
Absci Corporation (ABSI)
Phase 2 Readout: nereus
Vanda Pharmaceuticals Inc. (VNDA)
Phase 2 Readout: tibulizumab
Zura Bio Ltd (ZURA)
Phase 2 Readout: voquezna
Phathom Pharmaceuticals, Inc. (PHAT)
Phase 2 Readout: lasme-cel
Cellectis S.A. (CLLS)
Phase 2 Readout: tnx-4800
Tonix Pharmaceuticals Holding Corp. (TNXP)
Phase 2 Readout: Liver Treatment
Sagimet Biosciences Inc. (SGMT)
Phase 2 Readout: tvb-3567
Sagimet Biosciences Inc. (SGMT)
Phase 2 Readout: olvi-vec
GENELUX Corp (GNLX)
Phase 2 Readout: kpl-387
Kiniksa Pharmaceuticals International, plc (KNSA)
Phase 2 Readout: rese-cel
Cabaletta Bio, Inc. (CABA)
Phase 2 Readout: ep-104gi
EUPRAXIA PHARMACEUTICALS INC. (EPRX)
Phase 2 Readout: kt-621
Kymera Therapeutics, Inc. (KYMR)
Phase 2 Readout: spy072
Spyre Therapeutics, Inc. (SYRE)
Phase 2 Readout: envudeucitinib
ALUMIS INC. (ALMS)
Phase 2 Readout: pelareorep
ONCOLYTICS BIOTECH INC (ONCY)
Phase 2 Readout: casdatifan
Arcus Biosciences, Inc. (RCUS)
Phase 2 Readout: lam-001
Quince Therapeutics, Inc. (QNCX)
Phase 2 Readout: mze829
Maze Therapeutics, Inc. (MAZE)
Phase 2 Readout: sls009
SELLAS Life Sciences Group, Inc. (SLS)
Phase 2 Readout: fb102
Forte Biosciences, Inc. (FBRX)
Phase 2 Readout: inbrx-106
Inhibrx Biosciences, Inc. (INBX)
Phase 2 Readout: sabirnetug
Acumen Pharmaceuticals, Inc. (ABOS)
Phase 2 Readout: obexelimab
Zenas BioPharma, Inc. (ZBIO)
Phase 2 Readout: remlifanserin
ACADIA PHARMACEUTICALS INC (ACAD)
Phase 2 Readout: jade101
Jade Biosciences, Inc. (JBIO)
Phase 2 Readout: qrx003
Quoin Pharmaceuticals, Ltd. (QNRX)
Phase 2 Readout: com701
COMPUGEN LTD (CGEN)
Phase 2 Readout: al001
Alzamend Neuro, Inc. (ALZN)
Phase 2 Readout: agent-797
MiNK Therapeutics, Inc. (INKT)
Phase 2 Readout: abi-6250
ASSEMBLY BIOSCIENCES, INC. (ASMB)
Phase 2 Readout: aleniglipron
Structure Therapeutics Inc. (GPCR)
Phase 2 Readout: reqorsa
Genprex, Inc. (GNPX)
Phase 2 Readout: enobosarm
VERU INC. (VERU)
Phase 2 Readout: disc-0974
Disc Medicine, Inc. (IRON)
Phase 2 Readout: apg777
Apogee Therapeutics, Inc. (APGE)